Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Imaging
Carboxymethyldextran-A2-Gd-DOTA not suitable for use as MRI contrast agent
December 29th, 2005
Carboxymethyldextran (CMD)-A2-Gd-DOTA is not suitable for use in contrast-enhanced magnetic resonance imaging (MRI) of breast tumors. In a study from the United States, "carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels" of malignant and benign tumors. "Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted 3-dimensional spoiled gradient recalled sequence was performed in 30...
Source: Blood Weekly (2005-12-29)
|
